Q1 2019

Filed May 10, 2019 · 10-Q · 40 days after period end · 0001213900-19-008252

Q1 2019 · 10-Q

Revenue—

Net Income

-$191.41K

N/M vs Q1 2018

EPS Diluted

$0.00

— vs Q1 2018

Operating Income-$129,625N/M

Operating Cash Flow-$139,730N/M

Same quarter

Metric	Q1 2019	Q1 2018	Q1 2017	Q1 2016
Revenue	—	$13.32K	$7.44K	$31.53K
Net Income	-$191.41K	-$29.61K	-$64.59K	-$455.04K
EPS Diluted	$0.00	$0.00	-$0.03	-$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR